Condition: Acute Limb Ischemia · Sponsor: Supergene, LLC
Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.
This description comes directly from the study's public registry record.
Sergey S. Markin, MD, PhD · (906) 796-89-06 · amsemenof@gmail.com
Always discuss trial participation with your own doctor first.
| Kursk city emergency hospital | Kursk, Kursl Region, Russia | Recruiting |
| Sergiyev Posad Regional Clinical Hospital | Sergiyev Posad, Moscow Oblast, Russia | Recruiting |
| Kaliningrad Regional Clinical Hospital | Kaliningrad, Russia | Recruiting |
| Kazan City Hospital No. 7 | Kazan', Russia | Recruiting |
| S.S. Yudin City clinical hospital | Moscow, Russia | Recruiting |
| S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center | Moscow, Russia | Recruiting |
| Ufa Emergency City Hospital | Ufa, Russia | Recruiting |
| Volgograd City Clinical Hospital of Emergency #25 | Volgograd, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05372718